Skip to main content

Diseño computacional de nanomedicinas para el tratamiento del cáncer de mama (nanoPROTACs)

CPP2021-008597

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Transferencia de Conocimiento
Call Proyectos en Colaboración Público-Privada
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CANCERAPPY SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dual-drug codelivery gelatin-based hydrogel of ARV-471 and Palbociclib enhances synergistic effect in breast cancer treatment

  • Sevilla-Carrillo, Irene
  • Noblejas-López, María del Mar
  • Vázquez, José Antonio
  • Ocaña, Alberto
  • Bravo, Iván
  • Alonso-Moreno, Carlos
15 pages, 5 figures, 1 table.--The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions, Current therapeutic strategies for breast cancer increasingly focus on combination regimens. While targeting estrogen receptors (ER) has demonstrated clinical benefit, strategies to enhance ER inhibition and degradation are still needed. PROTAC technology enables the selective degradation of ER and other oncogenic proteins, but its clinical application may be limited by toxicity. In parallel, advanced drug delivery systems such as hydrogels are gaining attention for their ability to improve drug stability, reduce systemic toxicity, and enhance therapeutic performance. This study aims to co-encapsulate a CDK4/6 inhibitor, Palbociclib, and an ER-targeting PROTAC, ARV-471, within a hydrogel matrix as a proof-of-concept to demonstrate the feasibility and potential synergistic efficacy of this co-delivery strategy. Hydrogels were prepared using passive loading and tested for encapsulation efficiency and release in PBS (pH 7.4). Biological evaluation included MCF7, T47D, MCF10A, and HaCaT cell lines. Antiproliferative effects were assessed by MTT assay, together with 3D Matrigel growth, clonogenic survival, and flow cytometry for cell cycle and cell death. Drug synergism was determined by calculating the combination index (CI) at different molar ratios. Hydrogels achieved 100% encapsulation efficiency and preserved cytotoxicity against breast cancer cells. Notably, co-encapsulation of ARV-471 and Palbociclib produced a stronger synergistic effect than the free-drug combination. This study provides a proof-of-concept that hydrogel-based delivery can preserve the activity of individual drugs while amplifying their combinatorial effectiveness, paving the way for advanced in vivo validation, Carlos Alonso-Moreno and Iván Bravo’s lab is supported by CPP2021-008597 MICIU/AEI/https://doi.org/10.13039/501100011033 and Unión Europea NextGenerationEU/PRTR, JCCM and EU through INNOCAM and Fondo Europeo de Desarrollo Regional, FEDER (SBPLY/21/180501/000050), Universidad de Castilla-La Mancha (grant 2021-GRIN-31240), Asociación comarcal contra el cancer de Motilla del Palancar, ACEPAIN Foundation. Alberto Ocaña’s lab is supported by CRIS Cancer Foundation (AOF.C01), Instituto de Salud Carlos III (PI19/00808), ACEPAIN Foundation and CIBERONC, Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

A new guanidine-core small-molecule compound as a potential antimicrobial agent against resistant bacterial strains

  • Morata Moreno, Noelia
  • Pérez Tanoira, Ramón|||0000-0002-9816-3208
  • Del Campo Balguerías, Almudena
  • Carrillo Hermosilla, Fernando
  • Hernando Gozalo, Marcos|||0000-0003-2838-7270
  • Rescalvo Casas, Carlos|||0000-0003-3745-6661
  • Ocaña García, Verónica
  • Seguí, Pedro
  • Alonso Moreno, Carlos
  • Pérez Martínez, Francisco Carlos
  • Molina Alarcón, Milagros
11 p., The guanidine core has been one of the most studied functional groups in medicinal chemistry, and guanylation reactions are powerful tools for synthesizing this kind of compound. In this study, a series of five guanidine-core small molecules were obtained through guanylation reactions. These compounds were then evaluated against three different strains of Escherichia coli, one collection strain from the American Type Culture Collection (ATCC) of E. coli ATCC 35218, and two clinical extended-spectrum beta-lactamase (ESBL)-producing E. coli isolates (ESBL1 and ESBL2). Moreover, three different strains of Pseudomonas aeruginosa were studied, one collection strain of P. aeruginosa ATCC 27853, and two clinical multidrug-resistant isolates (PA24 and PA35). Among Grampositive strains, three different strains of Staphylococcus aureus, one collection strain of S. aureus ATCC 29213, and two clinical methicillin-resistant S. aureus (MRSA1 and MRSA2) were evaluated. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) experiments were reported, and the drop plate (DP) method was used to determine the number of viable suspended bacteria in a known beaker volume. The results from this assessment suggest that guanidine-core small molecules hold promise as therapeutic alternatives for treating infections caused by clinical Gram-negative and Gram-positive bacteria, highlighting the need for further studies to explore their potential. The results from this assessment suggest that the chemical structure of CAPP4 might serve as the basis for designing more active guanidine-based antimicrobial compounds, highlighting the need for further studies to explore their potential.